Chelsea Therapeutics Names Keith W. Schmidt Chief Commercial Officer

Chelsea Therapeutics Names Keith W. Schmidt Chief Commercial Officer

CHARLOTTE, N.C., Jan. 30, 2014 (GLOBE NEWSWIRE) -- Chelsea Therapeutics
International, Ltd. (Nasdaq:CHTP) today announced that Keith W. Schmidt has
been named Chief Commercial Officer, effective January 28, 2014. Mr. Schmidt
has served as a consultant to the Company since 2012.Prior to this role, he
was Vice President, Marketing and Sales, of the Company, a role he held since
joining Chelsea in 2006.Mr. Schmidt brings more than 30 years of experience
in domestic and international pharmaceutical sales and strategic marketing,
including the launch of many industry leading drugs.

Keith W. Schmidt
 Keith W. Schmidt, Chief Commercial

A photo accompanying this release is available at

"While we work toward the PDUFA action date for our Northera new drug
application, the Company will continue to pursue a dual path of preparing for
the potential commercial launch of Northera and actively assessing our
strategic alternatives," said Joseph G. Oliveto, President and Chief Executive
Officer of Chelsea Therapeutics."Keith has a strong understanding of the
neurogenic orthostatic hypotension orphan market, having led the team which
designed our initial commercial strategies and having more recently consulted
for the Company.He is ideally positioned to help execute a launch plan for
Northera, as well as to support our review of strategic alternatives."

"I am thrilled to rejoin the Chelsea team during this important time for the
Company," said Mr. Schmidt. "NOH remains an underserved orphan indication with
significant commercial potential, one that may be effectively served by a
highly targeted commercial effort."

About Symptomatic nOH

It is estimated that nearly 300,000 patients suffer from chronic symptomatic
nOH in the U.S. and EU combined. Symptomatic nOH is a chronic disorder that is
caused by an underlying neurogenic disorder, such as Parkinson's disease,
multiple system atrophy or pure autonomic failure. Symptoms of nOH include
dizziness, lightheadedness, blurred vision, fatigue, poor concentration, and
fainting episodes when a person assumes a standing position. These symptoms
often severely limit a person's ability to perform routine daily activities
that require standing or walking for both short or long periods of time.

About Northera

NORTHERA™ (droxidopa), the lead investigational agent in Chelsea Therapeutics'
pipeline, is currently under FDA review for the treatment of symptomatic
neurogenic orthostatic hypotension (nOH) in patients with primary autonomic
failure — an indication that includes a significant number of patients with
Parkinson's disease, multiple system atrophy (MSA) and pure autonomic failure
(PAF). Droxidopa is a synthetic catecholamine that is directly converted to
norepinephrine (NE) via decarboxylation, resulting in increased levels of NE
in the nervous system, both centrally and peripherally.

Droxidopa, developed by and licensed from Dainippon Sumitomo Pharma Co., Ltd.
(DSP), initially received Japanese approval in 1989 for the treatment of
frozen gait and dizziness on standing associated with Parkinson's Disease and
for the treatment of orthostatic hypotension, syncope or dizziness on standing
associated with Shy-Drager syndrome and Familial Amyloidotic Polyneuropathy.
In 2000, Droxidopa received expanded marketing approval to include prevention
of vertigo, dizziness and weakness associated with orthostatic hypotension in
hemodialysis patients.

About Chelsea Therapeutics

Chelsea Therapeutics (Nasdaq:CHTP) is a biopharmaceutical development company
that acquires and develops innovative products for the treatment of a variety
of human diseases, including central nervous system disorders. Chelsea
acquired global development and commercialization rights to droxidopa
(L-DOPS), or NORTHERA, from Dainippon Sumitomo Pharma Co., Ltd. in 2006,
excluding Japan, Korea, China and Taiwan. For more information about the
Company, visit

This press release contains forward-looking statements regarding future events
including our intention to pursue the development of NORTHERA™. These
statements are subject to risks and uncertainties that could cause the actual
events or results to differ materially. These include reliance on key
personnel and our ability to attract and/or retain key personnel; the risk
that FDA will not agree that our clinical trial results demonstrate the safety
and effectiveness of droxidopa; the risk that the FDA will not accept our
proposal regarding any trial or other data to support a new drug application;
the risk that the FDA will not approve the resubmitted NDA; the risk that our
resources will not be sufficient to conduct any study of Northera that will be
acceptable to the FDA; the risk that we cannot complete Study 401 or any other
additional study for Northera without the need for additional capital; the
risks and costs of drug development and that such development may take longer
or be more expensive than anticipated; our need to raise additional operating
capital in the future; our reliance on our lead drug candidate droxidopa; the
risk that we will not be able to obtain regulatory approvals of droxidopa or
our other drug candidates for additional indications; the risk of volatility
in our stock price, related litigation, and analyst coverage of our stock;
reliance on collaborations and licenses; intellectual property risks; our
history of losses; competition; market acceptance for our products if any are
approved for marketing.

The photo is also available via AP PhotoExpress.

         David Connolly
         LaVoie Group
         617-374-8800, Ext. 104
         Susan Kim
         Argot Partners

Chelsea Therapeutics Logo
Press spacebar to pause and continue. Press esc to stop.